Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing its earnings data after the market closes on Thursday, November 8th. Analysts expect Aurinia Pharmaceuticals to post earnings of ($0.17) per share for the quarter.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Aurinia Pharmaceuticals had a negative return on equity of 30.34% and a negative net margin of 12,536.05%. The company had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $0.05 million. On average, analysts expect Aurinia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
AUPH stock opened at $5.44 on Thursday. Aurinia Pharmaceuticals has a one year low of $4.41 and a one year high of $6.69. The firm has a market capitalization of $464.16 million, a PE ratio of -5.91 and a beta of 2.13.
Several research firms have recently commented on AUPH. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a report on Monday, July 16th. Cantor Fitzgerald set a $18.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 1st. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 8th. HC Wainwright boosted their target price on shares of Aurinia Pharmaceuticals to $15.00 and gave the stock a “buy” rating in a report on Monday, August 13th. Finally, ValuEngine raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $11.79.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Recommended Story: Institutional Investors
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.